{
    "clinical_study": {
        "@rank": "36659", 
        "arm_group": [
            {
                "arm_group_label": "measles-rubella and rotavirus vaccines", 
                "arm_group_type": "Experimental", 
                "description": "receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine and one 1.0 ml dose of oral Rotarix vaccine at 9 months of age"
            }, 
            {
                "arm_group_label": "measles-rubella vaccine", 
                "arm_group_type": "Active Comparator", 
                "description": "receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine at 9 months of age"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators aim to establish the non-inferiority of concomitant administration of\n      measles-rubella and rotavirus vaccines to measles-rubella vaccine given alone in terms of\n      measles seroconversion rates. The primary study hypothesis is the measles seroconversion\n      rate as defined by the percentage of children seroconverting to measles with a measles serum\n      antibody concentration of >=1:120 at 8 weeks post vaccination after the concomitant\n      administration of measles-rubella and rotavirus vaccines is non-inferior to that obtained\n      when measles-rubella vaccine is given alone in children 9 months of age who have received a\n      primary rotavirus vaccine series with the first dose between 6 and 10 weeks and the second\n      at least 4 weeks later and are seronegative for measles antibody in the pre-vaccination\n      sample."
        }, 
        "brief_title": "Coadministration of Measles-rubella and Rotavirus Vaccines", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Measles Antibody Seroconversion", 
            "Rubella Antibody Seroconversion", 
            "Rotavirus GMT", 
            "Rotavirus IgA Seropositivity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Measles", 
                "Rubella"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Child 9 months of age eligible for measles-rubella vaccination\n\n          -  documented evidence of a primary rotavirus vaccine series with first dose between 6\n             and 10 weeks of age and second dose at least 4 weeks after first dose\n\n          -  healthy infants free of chronic or serious medical condition as determined by history\n             and physical examination at time of study enrollment\n\n          -  parents/guardians of each participant are able to understand and follow study\n             procedures and agree to participate in study by providing signed informed consent\n\n        Exclusion Criteria:\n\n          -  hypersensitivity to any component of measles-rubella or Rotarix vaccine which would\n             preclude administration of the vaccine\n\n          -  history of intussusception, intestinal malformations, or abdominal surgery\n\n          -  known history of measles and/or rubella disease\n\n          -  history of previous receipt of measles and/or rubella vaccine\n\n          -  use of any immunosuppressive drugs or immunoglobulin and/or blood products since\n             birth or anticipated during study period\n\n          -  current enrolment in any other intervention trial or use of any investigational drug\n             or vaccine throughout the study period\n\n          -  any participant who reports planning to leave teh study area before the completion of\n             the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "11 Months", 
            "minimum_age": "9 Months"
        }, 
        "enrollment": {
            "#text": "480", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01700621", 
            "org_study_id": "HS677"
        }, 
        "intervention": [
            {
                "arm_group_label": "measles-rubella and rotavirus vaccines", 
                "description": "one 1.0 ml dose of oral rotavirus vaccine at 9 months of age", 
                "intervention_name": "Rotarix vaccine", 
                "intervention_type": "Biological", 
                "other_name": "rotavirus vaccine"
            }, 
            {
                "arm_group_label": [
                    "measles-rubella and rotavirus vaccines", 
                    "measles-rubella vaccine"
                ], 
                "description": "one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine", 
                "intervention_name": "measles-rubella vaccine", 
                "intervention_type": "Biological", 
                "other_name": "Measels and Rubella Virus Vaccine Live USP"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "rotavirus", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dhaka", 
                    "country": "Bangladesh"
                }, 
                "name": "ICDDR,B"
            }
        }, 
        "location_countries": {
            "country": "Bangladesh"
        }, 
        "number_of_arms": "2", 
        "official_title": "Non-interference and Safety of Concomitant Administration of Measles-rubella and Rotavirus Vaccines at 9 Months of Age in Rural Bangladesh", 
        "other_outcome": [
            {
                "description": "measles antibody level measured as the geometric mean concentration (GMC) of serum antibody to measles as measured by PRNT", 
                "measure": "measles antibody level (GMC)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks post vaccination"
            }, 
            {
                "description": "vaccine shedding defined as presence of vaccine-type rotavirus in stool at 4 (+/-1) and/or 7 (+/-1) days post rotavirus vaccination detected by ELISA and typed by RT-PCR", 
                "measure": "rotavirus vaccine shedding", 
                "safety_issue": "No", 
                "time_frame": "4 and/or 7 days post vaccination"
            }
        ], 
        "overall_official": {
            "affiliation": "International Centre for Diarrhoeal Disease Research, Bangladesh", 
            "last_name": "K Zaman, MBBS, PhD, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "ICDDR,B Data Safety Monitoring Board, Bangladesh:", 
                "ICDDR,B Research Review Committee, Bangladesh:", 
                "Center for Disease Control and Prevention, United States:"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "seroconversion defined as measles serum antibody concentration >=1:120  8 weeks post vaccination in a child seronegative pre-vaccination", 
            "measure": "measles serum antibody concentration", 
            "safety_issue": "No", 
            "time_frame": "8 weeks post vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01700621"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Immediate reactogenicity, solicited adverse events (diarrhea, fever, vomiting, loss of appetite, irritability, intussusception), and all serious adverse events will be recorded from time of vaccination through Day 56 post vaccination", 
                "measure": "safety", 
                "safety_issue": "Yes", 
                "time_frame": "Day 0 to Day 56 post vaccination"
            }, 
            {
                "description": "seroconversion defined as rubella serum IgG antibody concentration >=10 IU/mL 8 weeks post vaccination in a child seronegative pre-vaccination", 
                "measure": "rubella IgG antibody seroconversion", 
                "safety_issue": "No", 
                "time_frame": "8 weeks post vaccination"
            }, 
            {
                "description": "rotavirus IgA and IgG geometric mean titers (GMT) measured by ELISA before and after concomitant administration of measles-rubella and rotavirus vaccines", 
                "measure": "rotavirus IgA and IgG seroresponses", 
                "safety_issue": "No", 
                "time_frame": "Day 0 and Day 56"
            }, 
            {
                "description": "seroconversion defined as rotavirus serum IgA titer of >=1:20 U/mL measured by ELISA before and after concomitant administration of measles-rubella and rotavirus vaccines", 
                "measure": "rotavirus IgA seropositivity", 
                "safety_issue": "No", 
                "time_frame": "Day 0 and Day 56"
            }
        ], 
        "source": "PATH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PATH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}